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RESUMEN: 
El trabajo fin de grado que se describe a continuación forma parte de un proyecto basado en 
el estudio de la terapia fotodinámica con el objetivo de mejorar el tratamiento anti cáncer 
que actualmente es considerado como uno de los principales métodos para el tratamiento 
de muchas enfermedades. 
Por tanto, esta terapia fotodinámica puede ser utilizada para destruir células cancerígenas.El 
equipo de trabajo obtuvo el péptido KDKPPR que podría unirse con el receptor NRP-1 y por 
tanto con su co-receptor VEGFR-2 de gran importancia ya que ambos receptores son 
responsables de la regulación de la angiogénesis en el tratamiento del cáncer. 
Una vez formado el péptido se fueron sustituyendo los distintos aminoácidos por alanina 
para poder estudiar cuál de ellos tenía mayor importancia, obteniéndose los siguientes 
péptidos: KDKPPA, KDKPAR, KDKAPR, KDAPPR, KAKPPR, ADKPPR para evaluarlos mediante el 
método ELISA TEST y así seguir trabajando con el que tuviera más afinidad con NRP-1. 
PALABRAS CLAVE: 
Terapia fotodinámica, NRP-1,  síntesis de péptidos en fase sólida(spps), ELISA TEST, 
KDKPPR. 
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List of abbreviations: 
Table 1 :List of abbreviations. 
Symbol:       Meaning: 
A Alanine 
Ala Alanine 
Arg Arginine 
Asp Aspartatic acid 
Boc Tert.Butyloxycarbonyl or Tert.Butoxycarbonyl 
D Aspartatic acid 
DMF N,NDimethylformamide 
ELISA Enzyme-linked immunosorbent assay. 
Fmoc 9-Fluorenylmethoxycarbonyl 
HBr hydrobromicacid 
HBTU 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaﬂuorophosphate. 
HF Hydrofluoric acid 
HPLC High performance liquid chromatography 
K Lysine 
LCPM Laboratory macromolecular physical chemistry. 
LRGP Laboratory macromolecular physical chemistry. 
LRGP Reactions and laboratory engineering of processes. 
Lys Lysine 
mbar Milibars 
mg Milligrams 
min Minutes 
ml Milliliters 
mm Milimeters 
mmol Millimoles 
Mol.Wt Molecular weight 
nm Nanometers 
NMM 4-Methylmorpholine 99% C5H11NO. 
NMP 1-Methyl-2-pyrrolidinone. 
NMR Nuclear magnetic resonance spectroscopy. 
NRP-1 Neuropilin-1. 
P Proline. 
PDT Photodynamic therapy. 
ppm Parts per million. 
Pro Proline. 
PS Photosensitizer. 
R Arginine. 
ROS Reactive oxygen species. 
SPPS Solid phase peptide synthesis. 
TFA Trifluoroacetic acid. 
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TFMSA Trifluoromethanesulfonic acid. 
TIPS Triisopropylsilane. 
VEGFR Vascular endothelial growth factor. 
Symbol: Meaning: 
1H Proton. 
2D Second dimension. 
3D Third dimension. 
4D Fourth dimension. 
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1. INTRODUCTION: 
 
1.1. PHOTODINAMIC ANTICANCER THERAPY : 
 
1.1.1. PHOTODINAMIC THERAPY (PDT): 
 
Photodynamic therapy (PDT), sometimes called photochemotherapy, is considered to be 
one of promising methods in the treatment of many diseases, disorders and infections. In 
recent years, it has shown good capability in early cancertreatment and palliation of 
advanced cancer[1]. 
It is a form of phototherapy using nontoxic light-sensitive compounds that are exposed 
selectively to light (within specific wavelength), whereupon they become toxic to targeted 
malignant and other diseased cells(Figure 1)[2]. 
 
Figure 1- Schematic illustration of the mechanism of PDT 
Thephotosensitizer (PS) is injected systemically and after sufficient time to allow 
itsaccumulation in the lesion, light is delivered to produce reactive oxygen species (ROS). 
 
PDT involves three key components: 
o Photosensitizer (PS) 
o Light source 
o Tissue oxygen 
The combination of these three components leads to the destruction of nearby tissues 
following the exposure of the administered PS to lightin[3]. It is important that the 
wavelength of the light is appropriate for excitation of the photosensitizer in order to 
produce the cytotoxic reactive oxygen species“ROS”. 
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The Jablonski’s diagram in (Figure2) described the reaction that happens following PS 
exposure to light. The absorption of photons by PS causes its transformation from ground 
state to a higher energy level and the energy will be released either through the formation 
of fluorescence or being transformed into a triplet state which still contain a high energy 
level. The excited triplet state interacts with ground state molecular oxygen to form reactive 
oxygen species (ROS). This process may occur by (1) electron transfer to form superoxide 
anion or by (2) energy transfer to produce singlet oxygen molecules[4],which will in turn 
cause destruction of nearby cells. All these reactions happen in a very short time; in 
nanoseconds, and hence the PS needs to be localized in the targeted area of cancer. For this 
reason, targeting of PS becomes an interesting topic to be explored to improve the delivery 
of PS and this will nevertheless increase the efficacy of PDT[2]. 
 
 
 
Figure 2- Jablonski's diagram. 
 
Reactive oxygen species (ROS) are generated during PDT through two types of reactions: 
 
 Reaction (TYPE 1): 
The triplet (PS) can gain or donate an electron or hydrogen atom from a neighboring organic 
molecule and produce a super oxide anion radical (O2-)(Figure 3)[1, 2]. 
 
 
 
 
 
 
 
Figure 3 - Representation of the 
Type 1 photochemical 
mechanisms thought to operate 
in PDT. 
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 Reaction (TYPE2): 
In this case, PS in its triplet states can transfer its energy (3O2) directly to molecular oxygen 
(1O2)(Figure 4)[1, 2]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.2. MECHANISM OF PDT ADMINISTRATION AND ACTION: 
 
The method of PDT consists of 4 steps (Figure 5): 
 
o Step 1: Photosensitizer (PS) is injected into the bloodstream. 
 
o Step 2:PS is absorbed by cells all over the body but will concentrate more in cancer  
cells. 
o Step 3: After specific time length, PS will be accumulated in cancer cells and light at  
effective wavelength and light dose will be directed at them. 
 
o Step 4:PS will cause the production ofreactive oxygen species (ROS) that will  
eventually destroy the nearby cells. 
 
 
Figure 5- Steps to PDT. 
 
Figure 4 - Representation of the 
Type 2 photochemical mechanisms 
thought to operate in PDT. 
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1.1.3. ADVANTAGES AND DISADVANTAGESOF PDT: 
 
Many studies have shown that PDT could produce good treatment outcome in the 
treatments of different cancers or pre-cancerous solid massand the following advantages are 
usually associated with PDT over surgery or radiotherapy: 
 
Advantages: 
-  It is less invasive than surgery. 
-  It can be targeted very precisely. 
-  It has no long-term side effects when used properly and the therapeutic effects may 
become evidence in 48 to 72 hours. 
-  Usually it costs less than other cancer treatment options. 
-  It can be repeated many times at the same site if needed. 
 
Disadvantages: 
-  It does not have the ability to treat metastasized cancers. 
-  Currently approved PS molecules can only act on the surface of the skin or a few (mm)  
within it, so it could notbe used to treat a large cancer or cancers that have grown deep 
into the skin or other organs. 
 
1.2. PHOTOSENSITIZER: 
 
1.2.1. PHOTOSENSITIZER DISTRIBUTION IN TISSUES: 
Aphotosensitizeris a molecule thatcan be excited byabsorption of photon andis capable of 
transferringits energy to anacceptor molecule, and in the case of PDT, the energy is being 
transferred to oxygen molecules. Hence, in order to have a useful PS, the PS needs to have 
capability to absorb light in the visible region, with a bigger interest on molecules that have 
high visible absorbance in the red region (Figure 6).This is due to the fact that light could 
penetrate deeper into human tissues in this region and hence giving the possibility of using 
PDT for deep seated tumors[5]. 
 
Figure 6 - Light penetrationinto the tissueas a function ofwavelength. 
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1.2.2. TYPES OF PHOTOSENSITIZER: 
 
Historically, thecombination of a“drug”andlightin therapeuticapplications was started to be 
of interest since the beginning of 20th century, but it wasnot untilthe end of the century that 
« Food and Drug Administration, FDA » approved the first PS molecule for PDT application. 
Photofrin® which contained a mixture of haematoporphyrin derivatives was approved to be 
used for conditions includingpalliative treatment of esophageal cancer and non-small cell 
lung cancer. This product was also approved to be use in France, Germany, The Netherlands 
and Japan for the treatment of early and advanced stage of lung cancer, genitourinary and 
digestive tract cancer[6, 7]. 
 
• Porphyrins photosensitizer: 
 
Aspreviously explained,red absorption is the desired penetration wavelength due to better 
tissue penetration. To date, the most useful basic compounds as PS are porphyrins, chlorins, 
and pthalocyanines(Figure7). They have extensive aromatic systems and these molecules 
absorb light in the visible spectrum. There are also other classes of porphyrinoids use as PS 
for PDT such as: pheophorbides and texaphyrins[8]. 
 
 
 
Figure 7 - Basic chemical structure of porphyrin, chlorin, bacteriochlorin. 
 
1.3. ANGIOGENESIS IN CANCER: 
 
Angiogenesis is a term used to describe the formation of new blood vessels. This process can 
be controlled by chemical signals in the body and can operate in two ways: 
- repairing damaged blood vessels. 
- forming new blood vessels. 
 
Angiogenesis plays a fundamental role in the treatment of cancer because it is responsible of 
growth or expansion of all cells including cancer cells. 
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Metastasis is the process whereby cancer cells are disseminated throughout the body and 
can occur as a result of the presence of blood vessels following angiogenesis. Tumor uses the 
blood vessels to obtain oxygen and nutrients, and eventually transfer parts of the cells into 
blood circulation and the cells will continue growing in another part of the body.  
 
Currently, there are many different treatment options for cancer available in clinical settings 
such as surgery, chemotherapy, radiotherapy, hormonal therapy and immunotherapy, to 
name a few. Photodynamic therapy is now one of the treatment options available for certain 
types of cancer.  
PDT could be used to destroy the cancer cells itself through direct effect, or to destroy the 
blood vessels around the cancer cells through an indirect effect. In addition, the discovery of 
a peptide, KDKPPR by our research team in Nancy has opened up a possibility to directly 
target the Neropilin-1 (NRP-1) receptor. The NRP-1 is a co-receptor of VEGFR-2 and both are 
responsible in the regulation of angiogenesis process in cancer. 
Hence in this aspect, our team is currently working in improving PDT through targeting of 
the NRP-1 receptor described above. By doing so, it is believed that the delivery of PS  that 
will be conjugated with the targeting peptide could be better and ensuring improved PDT 
outcome[9]. 
 
1.3.1. DIFFERENTS RECEPTORS FOR ANGIOGENESIS: 
 
VEGFR or vascular endothelial growth factor receptors are a group of receptors responsible 
in the angiogenesis process occurring in human body. Its ligand, the VEGF (vascular 
endothelial growth factor) is the one responsible in ‘switching on’ angiogenesis process as 
needed.   
 
                                                                                                 VEGFR-1 
There are three variants of the VEGFR receptors:       VEGFR-2 
                                                                                                 VEGFR-3 
 
 
Eversince the discovery of VEGFs, its receptors VEGFR-1,-2, -3 and their co-receptor NRP-1, 
multiple studies were being conducted in order to understand more in term of their function 
in angiogenesis. The information available in the literature now has enables the formulation 
of active compounds to target this receptor and/or halt the progression of angiogenesis[10]. 
By doing so, these receptors could be used as a target point besides being able to stop the 
growth of cancer by blocking them. 
 
16 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
 
VEGFR-1: 
This receptor works in soluble form in the transmembrane of cells, being very effective for 
the treatment arthritis or rheumatism. 
 
VEGFR-2: 
It hasa key role inthe treatment ofphysiologicalandpathologicalangiogenesisby controlling 
theproliferation and migration ofendothelial cells. 
 
VEGFR-3: 
It is important at the beginning of the angiogenesis and embryogenesis.It regulates vascular 
and lymphatic endothelial cell function. 
 
Neuropilin-1: 
NRP-1 is a co-receptor of VEGFR-2 and they control the formation of new blood vessels 
through the process of angiogenesis[10]. 
 
 
 
Figure 8 - VEGF and VEGF receptors. 
 
 
1.4. VEGF & NRP-1 TARGETING PEPTIDES: 
 
VEGFfactors could be classified into different isoforms; VEGF - A, VEGF - B, VEGF - C, VEGF -
D, VEGF- E.Of all the possiblevariantsthe most importantforthe development 
ofangiogenesisisVEGF-A and it is also needed during pregnancyandinmaintainingblood 
pressure. VEGF-A itself has different isoforms, depending on the amino acids contained in 
the protein sequence in which they can be between 121-206 amino acids.There are five 
VEGF-A isoforms that are commonly found: VEGF-A121, VEGF-A145,VEGF-A165, VEGF-A189and 
VEGF-A206. Between all these isoforms, VEGF-A165 (Figure 9)isthe most important for 
pathological angiogenesis[11]. 
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Figure 9 - VEGF165 
 
In 2006, our team reported the discovery of a heptapeptide, ATWLPPR that had showed 
good ability to target the NRP-1 receptor (Tirand 2006). However, due to in vivo instability 
problem that aroused, the quest to find new NRP-1 targeting peptides with improved 
stability was started and five peptides were found to have good targeting capability. These 
peptides were discovered through different approaches involving docking simulation studies 
and ELISA tests[12, 13]. 
The Peptides are: 
 
*Four penta-peptides:  
DKPPR 
DKPRR 
TKPPR 
TKPRR 
*One hexa-peptide:  
CDKPRR 
2. OBJECTIVES: 
 
The discovery of the five peptides described above has given the possibility of improving PDT 
through peptide-based targeting. From all these peptides, DKPPR and TKPRR are two 
unpublished and novel findings for the research group. Based on ELISA test, DKPPR-PS-
conjugate and TKPRR-PS-conjugate showed improved receptor inhibitory capability as 
compared to ATWLPPR-PS conjugate (Kamarulzaman 2016).  
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Kamarulzaman[13]has described that the presence of Arginine (Arg, R) amino acid at C-
terminal position showed strong interaction with NRP-1. In an unpublished data, the 
addition of Lysine (Lys, K) in front of DKPPR, producing KDKPPR had shown further 
improvement of IC50 value against NRP-1 receptor. Hence, it was evidence that KDKPPR may 
have better targeting capability and it was indeed very interesting to further explore the 
characteristic of this peptide sequence.  
This project is designed to explore the importance of each amino acid in the KDKPPR 
sequence through a technique called Alanine-scanning. Through this technique, each amino 
acid was changed systematically with Alanine (Ala, A) and tested through ELISA test to 
investigate the importance of the substituted amino acid.  
In addition, there were also several other techniques that were learned through-out the 
process: 
 Learning how tosynthesizepeptideby using the technique« Solid phase peptide synthesis 
(SPPS) », the purification by RP-HPLC and subsequently storage of peptide. 
 
 Learning how to interprettheresults of « mass spectra » « NMR (Proton, TOCSY, COSY) » and 
« ELISA TEST ». 
 
 Evaluatingthe binding ability of the different peptides formed towards NRP-1 receptor 
through ELISA test and determining the best results. 
 
 Learning to work according to good laboratory practicein the laboratory and learning to 
work in team spirit.  
 
 
 
3. ALANINE SCANNING: 
3.1. METHOD: 
 
In this study, a technique called Alanine-scanning was implemented in which each amino 
acid in the KDKPPR sequence was systematically substituted with Ala to investigate the 
importance of the substituted amino acid.  Ala was used because it is the smallest chiral 
amino acid. In addition the substitution with Ala also eliminates side chain interactions 
without altering the conformation of main amino acid backbone[14]. 
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3.2. PEPTIDES TO SYNTHESIZE: 
 
Each amino acid in the KDKPPR sequence was replaced with Ala as presented in Figure 
below: 
 
Figure 10 - Peptides with alanine. 
 
In addition to the Ala-substituted peptides, three other peptides were also synthesized; (1) a 
peptide with Arg substituting Lys position - KDRPPR, (2) a retro peptide and (3) a retro-
inverso peptide (Figure-11).The retro-inverso peptide which is formed by D-amino acids is 
believed to have better stability as compared to the native KDKPPR. 
 
 
 
 
Figure 11 - Peptides to be formed. 
 
3.2.1. STRUCTURE AND CHARACTERISTICS OF THE SYNTHESIZED PEPTIDES: 
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Table 2: Structure and characteristics of the synthesized peptides. 
PEPTIDE STRUCTURE 
 
 
 
K-D-K-P-P-R 
 
 
 
 
 
 
K-D-K-P-P-A 
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K-D-K-P-A-R 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
K-D-K-A-P-R 
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K-D-A-P-P-R 
 
 
 
 
 
 
 
 
 
K-A-K-P-P-R 
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A-D-K-P-P-R 
 
 
 
 
 
 
K-D-R-P-P-R 
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R-P-P-K-D-K 
 
 
 
 
 
 
 
 
 
 
r-p-p-k-d-k 
 
 
 
 
 
 
**Note:Software called "ChemDraw"was used to draw the structure of the peptides. By 
using this software, theexact mass and molecular weight of each molecule could also be 
calculated directly. 
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4. LABORATORY OPERATIONS: 
 
4.1. THEORY: 
 
When designing a peptide, it is necessary to consider several aspects such as the amino acid 
composition, length of peptide, solubility and the application in which the peptides are to be 
used.It is also very important to know the characteristic of the amino acids forming the 
peptide, because they have a strong influence on the purification of the peptide and 
therefore also on the peptides’ solubility. 
For example: 
If a peptide contains many hydrophobic residues, its solubility in aqueous solution will be 
reduced and so their usability will also be reduced.In addition, a very hydrophobic peptide 
will also be more difficult to be obtained in large amounts with high purity. It is also 
recommended to have at least five amino acids when designing a peptide[15]. 
 
4.1.1. AMINO ACIDS AND THEIR PRINCIPAL CHARACTERISTICS: 
 
An amino acidis an organic molecule with an amide group(-NH2)and carboxyl group(-
COOH).(Figure12) 
 
Figure 12 - Basic structure of amino acids. 
 
The bond between two amino acids is called peptide bond and occurs by the condensation 
reaction between the amide group and the carboxyl group of another amino acid, releasing a 
molecule of water(Figure 13).Combination of multiple amino acids will form peptide. The 
synthesis of peptide is commonly occurring in cells, in an organel called ribosomes[16].  
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Figure 13 - Condensation reaction of a peptide bond. 
 
 
• These are the amino acids that were used in this work: 
 
 
o Alanine: 
Abreviated:Ala o A. 
Chemical formula:C3H7NO2 or CH3CH(NH2)COOH. 
Other names: 2-Aminopropanoic acid. 
 
Characteristics: 
Alanine is a non-polaramino acid. 
The isomer -L- is one of the 20 amino acids encoded by the human genetic code, while the 
isomer -D- occurs in bacterial cell walls and in some antibiotic peptides. (Figure 14)[16]. 
 
o Arginine: 
 
Abreviated:Arg o R 
Chemical formula: C6H14N4O2 
Other names:2-Amino-5-guanidinopentanoic acid. 
 
Characteristics: 
Arginine or L-arginine is a semi-essential amino acid. 
It is important in many metabolic processes and treatment of diseases of the heart and 
blood pressure. 
It is also used in diets for weight reduction and cholesterol.(Figure 15)[16]. 
 
 
 
 
 
 
 
 
Figure 15 - Arginine structure. 
 
     
 
 
Figure 14 - Alanine structure. 
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o Aspartic - acid: 
Abreviated:Asp o D 
Chemical formula:C4H7NO4  or HOOCCH(NH2)CH2COOH 
Other names:2-Aminobutanedioic acid. 
 
 
Characteristics: 
Aspartic acid is one essential amino acid not in humans. 
This amino acid has an overall negative charge and plays an important role in the cycle of 
citric acid and urea. 
From aspartic acid, it is possible to synthesize other amino acids as asparagine, arginine and 
lysine. (Figure 16)[16]. 
 
 
 
 
o Lysine: 
Abreviated:Lys o K  
Chemical formula:HO2CCH(NH2)(CH2)4NH2 
Other names: 2,6-Diaminohexanoic acid 
2,6-Diammoniohexanoic acid. 
 
Characteristics: 
Lysine is one of the amino acids synthesized by humans. 
Chemically it acts as a base. 
Animals could not synthesize lysine but they obtain this amino acid through ingestion of 
lysine-containing proteins. Plants on the other hand synthesize lysine from aspartic acid. 
(Figure 17)[16]. 
 
 
 
 
 
o Proline: 
Abreviated:Pro o P 
Chemical formula:C5H9NO2 
Other names:Pyrrolidine-2-carboxylic acid 
 
Characteristics: 
Proline is an imino acid. 
The primary amine on the α-carbon of semi-aldehyde glutamate forms a Schiff base with the 
aldehyde which is then reduced, yielding proline. (Figure 18)[16]. 
 
 
 
Figure 17 - Lysine structure. 
 
 
     
 
 
Figure 16 - Aspartic acid structure. 
 
      
 
 
Figure 18 - Proline structure. 
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• Table 3 summarize the physicochemical characteristics of all these amino acids: 
 
Table 3 : Characteristics of these amino acids. 
Amino Acid Code Hydropathy Charge pKa, NH2 pKa,COOH pK(R) Solubility 
(mg/mlwater). 
Alanine A Hydrophobic N 9.87 2.35  50 
Arginine R Hydrophilic + 9.09 2.18 13.2 50 
Aspartate D Hydrophilic - 9.6 1.88 3.65 5 
Lysine K Hydrophilic + 10.28 8.9 2.2 100 
Proline P Hydrophobic N 10.6 1.99  50 
 
 
4.2. EXPERIMENTAL METHOD: 
 
4.2.1. SOLID PHASE PEPTIDE SYNTHESIS (SPPS)Step 1: 
 
This methodwas pioneered byMerrifieldand at this moment itis the most accepted method 
for obtaining peptides and proteinssynthetically[15, 17]. 
 
• Method used: 
 
The first thingto do inthis methodis to calculatethe amounts ofamino acidsandreagentsto 
beused. This is presented in “Annex-1”. 
This design has three very important steps:Protection, Deprotection and Coupling. 
 
a) Protection:  
 
This stepis very important becauseamino acids havemultiplereactive groupswhichmust be 
protectedto avoidside reactionsandpreventramification. 
Protecting groups are added to the amino acids and only leave one free carboxyl group and 
N-terminal is also protected by Fmocgroup. The protection is important to ensure that the 
reactionwill proceed in the right direction[18]. 
These protecting groups are temporary and they are easily removed. Commonly, all the 
amino acids obtained commercially are readily protected(Figue-19). 
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Figure 19 - Amino acid functional group protection. 
 
There are two typesof protecting groups: N-α-protecting groups and C-terminal protecting 
groups. 
 
• N-α-protecting groups: 
 
FMOC (9-Fluorenylmethoxycarbonyl): 
It is used as a protector for synthesis routine.(Figure-20) 
 
 
 
 
 
 
 
 
 
 
BOC (Tert.Butyloxycarbonyl or Tert.Butoxycarbonyl): 
It is usedin complexsynthesis. 
Characteristics: 
- Stable to bases and nucleophiles. 
- Unaffected by catalytic hydrogenation.(Figure-21) 
 
 
*Note: Table 4 shows the necessary treatment for Fmoc and Boc according to the synthesis 
step. 
 
Table 4: Treatment for Fmoc and Boc in synthesis. 
Protecting Scheme Deprotection Coupling Cleavage Wash 
Boc/Bzl TFA Coupling agent in 
DMF. 
HF, HBr, TFMSA DMF 
Fmoc/tBut Piperidine TFA 
 
 
 
 
Figure 20 - Fmoc structure. 
 
     
 
 
Figure 21 - Boc structure. 
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• C-terminal protecting groups: 
 
Solid phase peptide synthesis does not use this kind of protection on resin because the resin 
works as a C-protecting group. There is also no protection on the C-terminal of amino acids 
because the synthesis necessitates the presence of free carboxylic group to form peptide 
bond. 
 
b) Deprotection: 
In this step, the Fmoc-protection of the N-terminal is removed by using piperidine. This is 
important to allow the formation of peptide bond with a new in-coming amino acid (which 
will have free carboxylic group).(Figure-22) 
 
 
Figure 22 - Deprotection of Fmoc group from N-terminal. 
 
FMOC: It is removed under basic conditions. Example: piperidine. 
BOC:it is removed under acidic conditions. Example: TFA. 
 
 
c) Coupling: 
 
The coupling step between two amino acids starts with activation of the C-terminal 
carboxylic acid. Several agents could be used and in this study, HBTU was used. Following 
this activation, peptide bond could be formed with the previously deprotected N-terminal of 
the first amino acid. (Figure-23) 
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Figure 23 - Diagram of peptide synthesis. 
 
*Note:“Annex-2”showed the steps used by the SPPS in peptide synthesis. It is the example 
of KDKPPR, but the synthesis of the other peptides also follows the same steps. 
 
• Machine: 
 
Name :« Intavis AG ResPep XL » Bioanalytical Instruments 
ResPep SL is a fully automated peptide synthesizer.It hasthe advantage 
thatmanypeptidescan be formedsimultaneouslyin parallel(Figue-24)[19]. 
 
 
 
 
 
Figure 24 - SPPS machine. 
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Parts of the machine: 
 
 
 
o Plate and Mini-Column Module: 
 
Each amino acid has a specific site where the needle goes automatically. 
 
 
 
 
o Needle: 
 
The needleis movingaboveall tubes, only taking thenecessary reactants in each synthesis step.  
 
o Columnreactor: 
 
Thisis the place where all the reactions take place and the peptide formed will be obtained. 
The resin is first added and then by the coupling of each amino acid will take place 
systematically.(Figue-25) 
 
 
 
 
 
 
Figure 25 - Parts of spps machine. 
 
• The amino acids, resins and other reactants used in this study, for the synthesis of peptide 
through SPPS. 
Amino acids: 
A:Fmoc-Ala-OH. 
D:Fmoc-Asp(OtBu)-OH. 
K:Fmoc-L-Lys(Boc)-OH. 
P:Fmoc-Pro-OH. 
r:Fmoc-D-Arg(Pbf)-OH. 
p:Fmoc-D-Proline. 
k:Fmoc-D-Lys-OH. 
d:Fmoc-D-Asp(OtBu)-OH. 
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Resins: 
A-Ѳ:Fmoc-L-Ala-wang resin. 
R-Ѳ:Fmoc-Arg(Pbf) – wang resin. 
k-Ø :Fmoc-D-Lys(Boc)-wang resin. 
Reagents: 
Activator: HTBU (Benzotriazole-1-yl) tetramethyluroniumhexafluorophosphate. 
Base: NMM (4-methylmorproline 99%) 
Capmix: Acetic anhydride. 
Piperidine. 
 
Solvent: 
 
DMF: N,N-Dimethylformamide. 
 
*Note: The synthesisrequires around 8hours and30minutesobtaining a peptide 
with6aminoacids. 
 
 
4.2.2. DRY + CLEAVAGE Step 2: 
 
At the end of the peptide synthesis, it is necessary to remove residual DMF that could still be 
present with the peptide. Hence, a drying step is usually carried out by using a vacuum 
pump. 
 Dry: 
• Machine and method used: 
 
The peptide is placedinto a dessicator that will be connected to a vacuum pump with 
nitrogen gas cooling system. (Figue-26) 
Duration: 2 hours. 
 
 
Figure 26 - Dessicator. 
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 Cleavage: 
• Machine and method used: 
 
The next step after drying is cleavage and this step is important in order to remove all 
protection groups of the synthesized peptide. This step will also remove the peptide from 
the solid support(Figure- 27). In our protocol, a combination of trifluoroacetic acid (TFA), 
triisopropylsilane (TIPS) and water was used (95% TFA: 2.5% TIPS:2.5% water). This cleavage 
mixture was added into the crude peptide in the column reactor and left to agitate at room 
temperature for two hours.(Figure 28) 
 
TFA = 5ml. 
TIPS  = 0.270ml. 
Water = 0.135ml. 
 
Figure 27 - Diagram of peptide cleavage after synthesis. 
 
Figure 28 - Agitator. 
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At the end of the reaction time, the cleaved peptide was precipitated in cold diethyl ether 
and subjected tolyophilization to obtain dried crude sample ready for purification by 
reverse-phase high performance liquid chromatography (RP-HPLC). 
 
4.2.3. LYOPHILISATION Step 3: 
 
• Method and machine used: 
This step involvesfreeze-drying the cleaved peptideto remove tracesof TFA, TIPS and water 
that arestill presence with the peptide. The lyophilisation process is formed bythree steps: 
freezing, primary drying andsecondary drying.The first step to do is freezing the 
peptidetohave itin the form ofice (solid state). This step is done by adding an excess amount 
of water into the sample and subsequently immersing it into liquid nitrogen[20]. The frozen 
water will then be removed through sublimation in which it is directly changed from solid 
state into gaseous state. A very low pressure is needed in order to have an efficient 
sublimation process and usually a good pressure of 0.01 mbar is needed. During the removal 
of water, TFA and TIPS are being removed together, leaving the crude peptide sample in 
dried form. 
 
 
Figure 29 - Lyophilizater. 
 
4.2.4. PURIFICATION - Reversed Phase High Performance Liquid Chromatography 
(RP-HPLC) Step 4: 
 
The dried crude peptides following lyophilization needs to be purified to separate any 
incomplete peptide sequence or any unwanted amino acids that might be 
presence.Depending on the characteristics of the peptides, size, charge and hydrophobicity; 
there are differentmethodsofpurification such as[21]: 
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• size-exclusion chromatography 
• ion exchange chromatography (IEC) 
• partition chromatography 
• High-performance liquid chromatography (HPLC). 
 
• Method and machine used: 
The purification method chosen in this study was RP-HPLC. This method allows the 
recuperation of purified peptide with good purity by using a purification column and HPLC 
chain (Figure-30).It is always better to have the highest purity possible in order to have a good 
analysis result by NMR, mass spectroscopy and especially important for biological ELISA 
study.  
 
Figure 30 - HPLC machine. 
 
 
The lyophilized sample (in step 3) was solubilised in the solvent used for the HPLC analysis 
and filtered before injecting into the HPLC. The Waters® HPLC as presented in (Figure 30)has 
both analytical and preparative inlets and this allow the analysis of the sample in analytical 
amount before proceeding to the purification by preparative column(Machery-Nagel VP 
150/21 NUCLEOSIL 100-5 C18). The purification necessitates a gradient elution program to 
have a more efficient compound separation. The details of the purification process are 
presented in Table 5: 
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Table 5:Details of the purification. 
 
 
 
 
 
 
 
 
 
 
 
• Calculation ofretention time: 
 
Time it takes each substance to leave the chromatographic system. This retention is 
dependent on the molecular characteristics of each compound. 
 
In this case to calculate the retention time must simply point the time it takes to appear our 
product in the chromatogram. 
 
4.3. CHARACTERIZATION OF THE PEPTIDES: 
 
4.3.1. MASS SPECTROMETRY (MS): 
 
• What does it consist of? 
Mass spectrometry (MS) isatechnique usedin laboratoriesto determine the presence of 
expected compound based on the mass/charge analysis of the sample. It is a simple and fast 
method in which the exact mass of the compound could be detected. The mass 
spectrometer available in the LCPM laboratory is: LCMS-2020 (Liquid chromatograth mass 
spectrometer). 
 
*Note:The exact mass of the compoundis calculated directlyin the"ChemDraw" program. 
 
 
 
 
Column Machery-Nagel  VP 150/21 NUCLEOSIL 100-5 C18 
Solvent Water/Acetonitrile/0.1% Trifluoroacetic acid 
 
Gradient 
Time (min) Water (% conc.) Acetonitrile (% conc.) 
0 95 5 
25 0 100 
30 0 100 
35 95 5 
Flow rate 12 ml/min 
Detector UV/Visible at 214 nm 
Pressure  1300 psi 
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4.3.2. NUCLEAR MAGNETIC RESONANCE (NMR): 
 
• What does it consist of? 
It is a group of scientific methods used to study and help to deduce the structure of organic, 
organometallic or biological molecules.This methodallows studying the presence of 
isotopeelement such asproton (1H) and carbon(13C). It is a non-destructive method because 
the sample keeps all its properties after being treated.It also hasthe advantage that it could 
produce structural informationin more than onedimension NMR(2D, 3D, 4D) and the results 
could be obtained in relatively quick and easy manner. 
 
In this study, three different spectrums were produced by NMR method to help in the 
confirmation of peptide structures. The presence of all amino acid needs to be confirmed 
especially in this study whereby each amino acid is being changed systematically.  
 
One-dimensional(1D) spectrum – Proton NMR (1H): It gives information on all the hydrogen 
atoms present in the molecule. 
Two-Dimensional(2D) spectrum (TOCSY, COSY):therelationship between different hydrogen 
atoms in the molecules was studied. 
The NMR available in the LCPM laboratory is: BRUNKER (300MHz / 52mm). 
 
The following images described in general the NMR shift (in ppm) of each proton from all 
amino acids used in this study. In TOCSY analysis, the correlation between two protons from 
unconnected carbons could be seen, whereas COSY only allows the correlation between 
protons from connected carbons. As an example, in the structure of alanine, there are three 
types of protons; the alpha-proton, beta-proton and proton for amide group. The correlation 
between beta-proton and amide-proton could be observed in TOCSY (red diamond spot) 
whereby in COSY, only correlation between beta-proton and alpha-proton could be seen 
(blue round spot) and subsequently another spot could be seen that correlate between 
alpha-proton and amide-proton. This analysis was done by using a program called DIA, which 
allows correlation to be done through formation of vertical and horizontal lines. 
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Figure 31 - Representation of amino acids in Tocsy and Cosy. 
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* Note:An example of the results obtained in the NMR can be seen in the next section of 
work. 
 
4.3.3. ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA TEST): 
 
• What does it consist of? 
 
It is a biological test that allows the detection of specific antigens that interact with specific 
antibody. It could be use in common antigen-antibody detection such as in HIV-detection or 
pregnancy tests or in other conditions such as in this study whereby the affinity of our 
synthesized peptide (antigen) will be tested on targeted NRP-1 receptor (antibody). An 
enzyme-linked antibody used in this study will catalyze a colour change that will indicate 
positive reaction.This technique was conducted by a team of biologists in our research 
group. 
 
 
Figure 32 - Steps ELISA test. 
5. RESULTS: 
5.1. PURIFICATION (HPLC): 
 
Table 6 :Retention time of the synthesized peptide in analytical and preparative HPLC. 
Peptide Retention time-analytical (min) Retention time-preparative (min) 
KDKPPR 6.06 5.72 
KDKPPA 6.71 6.81 
KDKPAR 4.56 4.92 
KDKAPR 4.84 5.56 
KDAPPR 4.41 4.46 
KAKPPR 4.52 4.56 
ADKPPR 4.32 4.63 
KDRPPR 5.75 6.38 
RPPKDK 4.66 4.62 
rppkdk 4.59 4.62 
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5.2. MASS SPECTRA: 
 
Table 7 :Results mass spectra. 
Peptide Mass expected Mass observed 
M[+] M[2+]  M[+] 
KDKPPR 740.43 370.72 KDKPPR 740.43 
KDKPPA 655.37 328.19 KDKPPA 655.37 
KDKPAR 714.42 357.71 KDKPAR 714.42 
KDKAPR 714.42 357.71 KDKAPR 714.42 
KDAPPR 683.37 342.19 KDAPPR 683.37 
KAKPPR 696.44 348.72 KAKPPR 696.44 
ADKPPR 683.32 342.16 ADKPPR 683.32 
KDRPPR 768.44 384.72 KDRPPR 768.44 
RPPKDK 740.43 370.72 RPPKDK 740.43 
rppkdk 740.43 370.42 rppkdk 740.43 
 
5.3. NUCLEAR MAGNETIC RESONANCE (NMR): 
 
KDKPPR -  Proton 
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KDKPPR - Cosy 
 
KDKPPR - Tocsy 
 
 
 
43 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
 
5.4. ELISA TEST: 
 
I am waiting for the results. 
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5.5. CALCULATION OF THE YIELD OBTAINED: 
 
𝐄𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐲𝐢𝐞𝐥𝐝 (𝐦𝐠) = 𝐧 (𝐦𝐦𝐨𝐥)  × 𝐌𝐰 
 
Table 8 :Yieldobtained. 
PEPTIDE Amount obtained (mg) Percentage (%) 
KDKPPR 39.00 49.15 
KDKPPA 51.00 77.93 
KDKPAR 47.44 66.49 
KDKAPR 35.37 49.58 
KDAPPR 17.43 25.58 
KAKPPR 22.00 31.63 
ADKPPR 41.00 60.08 
KDRPPR 39.00 50.82 
RPPKDK 48.00 64.92 
rppkdk 36.13 48.86 
 
5.6. SUMMARY TABLE OF RESULTS: 
 
Table 9 :Summary of results. 
 
6. DISCUSSION and CONCLUSIONS: 
 
Due to the inability to obtain ELISA result at the end of the attachment, it is not possible to 
draw any conclusion of the characteristics of the peptide synthesized, and of the importance 
of each amino acid in the interaction of KDKPPR on neuropilins-1 receptor, which is the main 
aim of alanine-scanning approach taken in this project. In due course, the discussion and 
conclusion will be made once the ELISA result is obtained.  
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8. ANNEX: 
8.1. ANNEX-1: Amounts of amino acids used in SPPS 
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8.2. ANNEX-2:Metod used in spps. 
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8.3. ANEXX-3: Results of purification. 
 
KDKPPR 
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KDKPPA 
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KDKPAR 
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KDKAPR 
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KDAPPR 
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KAKPPR 
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ADKPPR 
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KDRPPR 
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RPPKDK 
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rppkdk 
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8.4. ANNEX-4: Mass spectrum graphics. 
 
KDKPPR: 
 
 
KDKPPA: 
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KDKPAR: 
 
 
 
 
 
KDKAPR: 
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KDAPPR: 
 
 
 
 
 
 
KAKPPR: 
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ADKPPR: 
 
 
 
KDRPPR: 
 
 
 
RPPKDK: 
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rppkdk: 
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8.5. ANNEX-5:NMR graphics. 
 
KDKPPR-Proton 
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KDKPPR-Cosy 
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KDKPPR-Tocsy 
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KDKPPA-Proton 
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KDKPPA-Cosy 
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(2015/2016) 
 
KDKPPA-Tocsy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDKPAR-Proton 
 
 
71 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDKPAR-Cosy 
 
 
 
 
72 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDKPAR-Tocsy 
 
 
 
 
73 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDKAPR-Proton 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDKAPR-Cosy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDKAPR-Tocsy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDAPPR- Proton 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
 
KDAPPR-Cosy 
 
 
 
78 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDAPPR-Tocsy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KAKPPR-Proton 
 
 
80 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KAKPPR-Cosy 
 
 
81 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KAKPPR-Tocsy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
ADKPPR-Proton 
 
 
83 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
ADKPPR-Cosy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
ADKPPR-Tocsy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDRPPR-Proton 
 
 
86 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDRPPR-Cosy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
KDRPPR-Tocsy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
RPPKDK-Proton 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
RPPKDK-Cosy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
RPPKDK-Tocsy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
rppkdk-Proton 
 
 
92 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
rppkdk-Cosy 
 
 
93 
 
Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
rppkdk-Tocsy 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
9. PERSPECTIVE: 
 
Once just built the 10 peptides described above it want to continue studying what the best 
stability presented and will continue to change the various amino acids which form the 
peptide. 
That is why it was started designing with the same steps the following peptide: 
K-d-K-P-P-R 
 Structure: 
K-d-K-P-P-R 
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Final Project.                                                                                                                                                  LONGARELA, Eugenia Teresa                                                                               
(2015/2016) 
 
With this peptide we were able to purify and send tests of mass spectra and NMR with the 
following results: 
 Purification (HPLC) : 
 
 Mass spectra : 
 
*Note: the result is still uncharacterized,We are awaiting the result of mass spectra to know 
which is our product 
 
Because of time it has not been able to send ELISA test. 
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